Mukesh Ambani’s Reliance Industries Ltd. is working on a new COVID-19 drug. The Mukesh Ambani-led conglomerate is working towards cheaper testing kits. This will help curb the pathogen which has ravaged India in the past year.
RIL, as per its annual report, is exploring use of a tapeworm drug, Niclosamide, as a cure for COVID-19.
Its diagnostic kits – R-Green and R-Green Pro have been approved by India’s apex medical research body. Not only this, but RIL has also designed a process to make sanitisers at one-fifth the market cost, says Reliance in the report.
The retail group’s efforts come after India emerged the pandemic’s epicenter.
The deadly second wave claimed several lives and left a trail of destruction even in the Indian economy.
Experts are now warning against a possible third wave of infections.RIL is also trying to address ventilator shortages across India. Moreover, it is designing medical-grade oxygen generators with five to seven liter capacity per minute, as per the report.
To meet the shortage of oxygen in the country, Reliance had repurposed its plants in Jamnagar, world’s biggest oil refinery site, to produce medical-grade oxygen.
ALSO READ | COVID-19: Reliance Becomes Largest Producer Of Medical-Grade Liquid Oxygen From A Single Location
